Exosomes from Mesenchymal Stem Cells for Alzheimer's Treatment
Summary
USPTO published patent application US20260097080A1 covering exosomes isolated from mesenchymal stem cells for reducing inflammation and treating Alzheimer's disease. The application claims exosomes exposed to conditioned media with microglial cells in the presence of LPS or beta-amyloid oligomer. This is a publication of a pending application, not a granted patent.
What changed
USPTO published patent application US20260097080A1 relating to exosomes isolated from mesenchymal stem cells for Alzheimer's treatment. The application covers exosomes exposed to conditioned media in which microglial cells are cultured with LPS or beta-amyloid oligomer, with claims for reducing inflammation and treating Alzheimer's disease. Inventors include Eleni Markoutsa, Shyam S. Mohapatra, and Subhra Mohapatra.
Affected parties including pharmaceutical companies, biotech firms, and healthcare providers developing stem cell-based therapies for neurodegenerative diseases should monitor this application's progress. Once granted, the patent would provide exclusionary rights covering the described exosome compositions and methods of treatment. Parties conducting R&D in this space should consider freedom-to-operate analysis and potential licensing needs.
What to do next
- Monitor for patent grant or rejection
- Review claims for freedom-to-operate analysis
- Assess IP landscape for competing applications
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
EXOSOMES ISOLATED FROM MESENCHYMAL STEM CELLS AND USES THEREOF
Application US20260097080A1 Kind: A1 Apr 09, 2026
Inventors
Eleni Markoutsa, Shyam S. Mohapatra, Subhra Mohapatra
Abstract
The present disclosure relates to exosomes isolated from mesenchymal stem cells exposed to a conditioned media in which microglial cells are cultured in the presence of lipopolysaccharide (LPS) or a beta-amyloid oligomer and uses thereof for reducing inflammation and for treating Alzheimer's disease.
CPC Classifications
A61K 35/28 A61K 31/203 A61K 31/7088 C12N 5/0662 C12N 15/113 C12N 2310/113 C12N 2502/086
Filing Date
2025-10-06
Application No.
19350180
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.